Medtronic Inc (MDT) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Medtronic Inc (MDT)

90.65

-0.58 (0.64%)

as of Aug 31, 2026, 8:00:00 pm Market Open.

183 watching

Investor Insights

Aug 31, 2026, 12:00 am

This summary was created by AI, based on 4 opinions in the last 12 months.

Medtronic Inc (MDT) is viewed positively by various experts, benefiting from demographic tailwinds as the aging Baby Boomer population becomes a relevant customer base. The company is currently trading at a price-to-earnings (PE) ratio of 15x, complemented by a solid 7% free cash flow yield and anticipated earnings growth of 8-9% over the next several years. Recent momentum has seen the stock rise 20% in the past three months, suggesting strong market interest as it approaches its upcoming earnings report. Despite competition, particularly from Boston Scientific, Medtronic's diversified portfolio sets it apart from peers who may lack similar R&D capabilities. While short- to medium-term outlook is optimistic, some experts caution against viewing Medtronic as a long-term investment due to potential challenges in maintaining leadership and innovation in the industry.

Consensus

Positive

Valuation

Undervalued

Similar

Stryker,SYK

BUY

Allan Tong’s Discover Picks The Medtronic Stock is one of the largest medical device companies on the globe. It pays a decent dividend of 2.3%, which has grown in the last 28 straight years. MED trades at a 22x PE and has a price target of $110.17, $8 higher than Monday’s trade. MED beat three of its last four quarters, missing its last reported EPS of 68 cents by 10 cents. It boasts a profit margin of 16.56%. Read Cybersecurity Stocks, Clean Energy Stocks and Medical Device Stocks: Little-Known Picks for our full analysis.

TOP PICK

One of the largest device companies in the world. There's a lot of pent-up demand coming for surgeries. It was $120, and now it's around $100. Should see $120 again. Yield is 2.29%. (Analysts’ price target is $110.50)

BUY

Medtronic vs. Stryker Both make medical devices, and have been impacted by COVID, because operations have been delayed. But now those ops are coming back. She owns JNJ instead, which includes a medical devices division. Unless there's a sharp uptick in the virus that shuts down hospitals again, demand for medical devices should rise and should even ramp in the near future.

HOLD

It has grown its dividend 28 consecutive years. Not all of its businesses will be firing. It will not get the same lift because it is not 100% exposed to COVID-19. After COVID the whole diagnostic space will be an interesting one. The dividend is probably relatively safe.

PAST TOP PICK

(A Top Pick Oct 02/19, Up 7%) They reported today and miss expectations. It's a big global company. There's global demand for their medical devices; in Asia, for instance, there's rising heart disease. So, Medtronic can fulfill this demand.

BUY

A large cap diversified company. Their recent acquisition to get into the robotic spine is positive. It has everything for tools and devices, including pacemakers. The chart looks great. This would be the one to own in the space.

BUY

Good company. Biggest product is pacemakers. Trades at 19x earnings. Good stock price stability. Trades attractively against peers. Given the multiple, and predictability of earnings, you should look at a 10% return or greater over time.

TOP PICK

They built the first pacemaker and have gone on to make several similar devices. They have gone global. Places like India need these devices for heart disease, for example. The CEO is from Bangladesh and understands this vast market. They are moving from selling the device to improving people's health. If they succeed, they will be hugely profitable. (Analysts’ price target is $116.38)

Wealthica Track your Stocks in your Watch List

BUY

The stock couldn’t look any better. An absolute buy and hold. It took a long time to break through $100 but they’ve done it. Would be a buyer here.

HOLD

Don't sell it just to go into a Merck. Add to your diversity instead by buying a basket. Likes Medtronic. Diversified. Into robotic surgery. 8% EPS growth. Relatively inexpensive. Very large, so you don't get the same growth as smaller companies.

BUY

Likes it very much. Thought bought Covidien, a medical device maker, a few years back. They're executing very well, such as their diabetes franchise which boosted their guidance recently to 5.5% growth in 2019. Valuation good at 17.5x vs. peers. Many of their products are essential services which is anothe tailwind.

PAST TOP PICK

(A Top Pick November 13, 2017. Up 24%). He owned this as a diversified play on the medical device market. He sold the stock when it reached $90 and used the proceeds to buy Boston Scientific instead.

WEAK BUY

He likes medical device manufacturers. It seems they are taking market share in a booming market. They are well diversified. The company continues to put up great numbers.

BUY

Likes this. One of the most dominant medtech companies, diversified from hips and knees to cardio. Good 15x forward earnings and a stable dividend yield. It's an economy of scale game in medtech, and MDT is well-positioned. Great
balance sheet and growth profile.

COMMENT

A dividend aristocrat, gradually increasing the dividend every year. They are in medical devices. Any increase in surgery, hospital time and heart disease would be an upside for this story. It’s been a relative laggard for the group, but has been a very good performer longer-term, and has rewarded shareholders very well. Sees this as a mutual fund of device companies.

Showing 46 to 60 of 127 entries

Most Recent Experts

Andrey Omelchak

LionGuard Capital Management

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Capital Wealth Planning

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Medtronic Inc (MDT)